CYTOGEN CORP Form 8-K May 04, 2004

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 4, 2004

CYTOGEN CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware 000-14879 22-2322400

(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer of Incorporation) Identification No.)

650 College Road East, CN 5308, Suite 3100, Princeton, NJ 08540

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (609) 750-8200

(Former Name or Former Address, if Changed Since Last Report)

ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On May 4, 2004, Cytogen Corporation announced its financial results for the quarter ended March 31, 2004, and reaffirmed its previously provided financial guidance for 2004. The full text of the May 4, 2004 press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Edgar Filing: CYTOGEN CORP - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CYTOGEN CORPORATION

By: /s/ Michael D. Becker

Michael D. Becker

President and Chief Executive Officer

Dated: May 4, 2004

EXHIBIT INDEX

Exhibit No.	Description

99.1 Press release dated May 4, 2004